CVS Health Co. (NYSE:CVS) Shares Sold by Moors & Cabot Inc.

Moors & Cabot Inc. decreased its position in shares of CVS Health Co. (NYSE:CVS - Free Report) by 26.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 103,168 shares of the pharmacy operator's stock after selling 37,746 shares during the quarter. Moors & Cabot Inc.'s holdings in CVS Health were worth $4,631,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of CVS. MidAtlantic Capital Management Inc. acquired a new position in shares of CVS Health during the 3rd quarter valued at about $25,000. Ridgewood Investments LLC boosted its position in shares of CVS Health by 255.7% during the 4th quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator's stock valued at $28,000 after acquiring an additional 450 shares during the last quarter. Stonebridge Financial Group LLC purchased a new stake in CVS Health in the 4th quarter valued at about $28,000. Legacy Investment Solutions LLC purchased a new stake in CVS Health in the 3rd quarter valued at about $31,000. Finally, Financial Perspectives Inc raised its holdings in CVS Health by 137.5% in the 4th quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator's stock valued at $36,000 after buying an additional 466 shares during the period. Institutional investors and hedge funds own 80.66% of the company's stock.

Analyst Ratings Changes

Several brokerages recently issued reports on CVS. Wells Fargo & Company boosted their price objective on shares of CVS Health from $68.00 to $73.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Edward Jones upgraded shares of CVS Health from a "hold" rating to a "buy" rating in a report on Thursday, January 30th. Wolfe Research boosted their price objective on shares of CVS Health from 67.00 to 70.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. Leerink Partnrs upgraded shares of CVS Health from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 12th. Finally, TD Cowen boosted their price objective on shares of CVS Health from $73.00 to $80.00 and gave the company a "buy" rating in a report on Monday, November 25th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $69.83.

Remove Ads

Insider Activity

In other news, SVP James David Clark sold 7,513 shares of the firm's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now owns 8,394 shares in the company, valued at approximately $556,941.90. This trade represents a 47.23 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael F. Mahoney acquired 30,000 shares of CVS Health stock in a transaction that occurred on Tuesday, February 18th. The stock was purchased at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the transaction, the director now owns 39,356 shares of the company's stock, valued at $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.24% of the company's stock.

CVS Health Stock Performance

Shares of CVS opened at $64.98 on Wednesday. The stock has a 50 day moving average price of $57.24 and a 200 day moving average price of $56.83. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. The company has a market capitalization of $81.92 billion, a price-to-earnings ratio of 17.75, a price-to-earnings-growth ratio of 0.98 and a beta of 0.53. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $80.75.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Research analysts predict that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Thursday, January 23rd were issued a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 4.09%. The ex-dividend date was Thursday, January 23rd. CVS Health's payout ratio is currently 72.68%.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.